HRC Ledger
Award

SUPPLY of LUTATHERA® (lutetium Lu 177 dotatate) and PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan)

Buyer
Defense Health Agency
Awarded to
Not stated
Agency
Defense Health Agency
Estimated value
$480,120
Clinical Utility: It is used for targeted radioligand therapy for specific types of prostate cancer within the Nuclear Medicine Division of the Department of Radiology at WRNMMC. Novartis Pharmaceuticals Corporation is the sole source for Pluvicto. Therefore, the recommended course of action is to award a contract directly to Novartis. This approach is deemed to be in the government's best interest to ensure the seamless delivery of these critical supplies and maintain continuity of patient care at WRNMMC. The acquisition will be treated as a sole-source procurement.

Key dates

Award date
September 30, 2026
Posted
October 8, 2026

Who is this buyer

Department of Defense

Organization

Defense Health Agency

Buying history

  • Records738 total
  • Opportunities / awards15 / 562
  • Value range$0 – $300,000,000
  • ActiveApril 13, 2026 – October 27, 2026

What they buy

  • Clinical (687)
  • Administrative (46)
  • Insurance (5)

Set-asides used

  • No Set aside used (114)
  • Small Business Set Aside - Total (26)
  • 8(a) Set-Aside (FAR 19.8) (3)
  • WOSB Program Set-Aside (FAR 19.15) (2)

Who holds their work today

  1. DELOITTE CONSULTING LLP1 win · $300,000,000 · last August 6, 2026
  2. A SQUARE GROUP LLC1 win · $300,000,000 · last August 6, 2026
  3. GREAT HILL SOLUTIONS, LLC1 win · $300,000,000 · last August 6, 2026
  4. VISTA GLOBAL SOLUTIONS, LLC1 win · $300,000,000 · last August 6, 2026
  5. GENERAL DYNAMICS INFORMATION TECHNOLOGY, INC.1 win · $300,000,000 · last August 6, 2026

Also open from this buyer

View source document →

Source link on sam.gov.

Source record

Buyer type
Federal
Jurisdiction
Federal (US)
Category
Clinical
Set-aside
Not stated
NAICS
Not stated
PSC
Not stated